

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心瑋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

**ANNOUNCEMENT IN RELATION TO COMPLETION OF
INDUSTRIAL AND COMMERCIAL REGISTRATION FOR
REGISTERED CAPITAL ALTERATION AND
AMENDMENTS TO ARTICLES OF ASSOCIATION**

References are made to the announcements of Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”) dated December 12, 2025, January 16, 2026 and May 21, 2026, respectively, and the circular (the “**Circular**”) of the 2026 first extraordinary general meeting, the 2026 first class meeting of H shareholders and the 2026 first class meeting of unlisted shareholders of the Company dated December 31, 2025, in relation to, among other things, (i) the proposed issuance of the Domestic Shares under the Specific Mandate (the “**Issuance**”); and (ii) the grant of authority to the Board and its authorized persons to handle matters in relation to the Issuance. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

On May 14, 2026, the Company has received the “Approval for the Registration of Issue of Shares by Shanghai HeartCare Medical Technology Corporation Limited to Specific Recipients” (Zheng Jian License [2026] No. 1153) from China Securities Regulatory Commission. The proceeds from the Issuance have been fully paid. Upon completion of the Issuance, the registered capital of the Company will change from RMB38,834,408 to RMB39,834,408.

Recently, the Company has completed registration of the alteration of its registered capital with industrial and commercial authority in respect to the Issuance and obtained a renewed business license from Shanghai Municipal Administration for Market Regulation. The Company completed the amendments to the relevant provisions of the Articles of Association and filing with Shanghai Municipal Administration for Market Regulation simultaneously. Details of the amendments to the Articles of Association are set out as follows:

Article No.	Before amendment	After amendment
Article 19	<p>The Company was authorized by the securities regulatory authority under the State Council on May 13, 2021 to issue no more than 12,356,000 overseas listed foreign shares to overseas investors. WANG Guohui (王國輝), DING Kui (丁魁), ZHANG Kun (張坤), Ningbo Meishan Bonded Area Speed Investment Partnership (LP) (寧波梅山保稅港區斯彼德投資合夥企業(有限合夥)), Ningbo Meishan Bonded Area Sinena Investment Partnership (LP) (寧波梅山保稅港區新勝意納投資合夥企業(有限合夥)), Ningbo Meishan Bonded Port Area Xinwei Investment Management Partnership (LP) (寧波梅山保稅港區心瑋投資管理合夥企業(有限合夥)), Ningbo Tongchuangsuwei Investment Partnership (LP) (寧波同創速維投資合夥企業(有限合夥)), Ningbo Meishan Bonded Port Area Kaiyuan Investment Management Partnership (LP) (寧波梅山保稅港區楷遠投資管理合夥企業(有限合夥)), Hangzhou Hidea Mingde Venture Capital Partnership (LP) (杭州海達明德創業投資合夥企業(有限合夥)), Hangzhou Huipu Direct Equity Investment Partnership (LP) (杭州匯普直方股權投資合夥企業(有限合夥)), Horgos Dadao Venture Capital Corporation Limited (霍爾果斯達到創業投資有限公司), Jiangsu Sharewin Heike Healthcare Investment Fund (LP) (江蘇盛宇黑科醫療健康投資基金(有限合夥)), Zhangjiagang Grandyangtze Jiyuan Investment Partnership (LP) (張家港國弘紀元投資合夥企業(有限合夥)), SDIC Unity Capital National Emerging Industry Venture Capital Guiding Fund (LP) (國投創合國家新興產業創業投資引導基金(有限合夥)), Tianjin Huajinjintian Medical Healthcare Venture Capital Partnership (LP) (天津華金錦天醫藥醫療創業投資合夥企業(有限合夥)), LYFE Columbia River Limited, LYFE Columbia River Limited, Zhuhai Sherpa Phase I Equity Investment Partnership (LP) (珠海夏爾巴一期股權投資合夥企業(有限合夥)), SherpaStrokemed Company Limited, Shanghai Weiyu Enterprise Management Consulting Partnership (LP) (上海瑋鈺企業管理諮詢合夥企業(有限合夥)), Shanghai Weiyun Enterprise Management Consulting Partnership (LP) (上海瑋鑒企業管理諮詢合夥企業(有限合夥)), CICC Pucheng Investment Corporation Limited (中金浦成投資有限公司), REN Yi (任毅), LYFE Ohio River Limited, Elbrus Investments Pte. Ltd., Raritan River Limited, LBC Sunshine Healthcare Fund II L.P. and SherpaStrokecure Limited converted the 24,963,954 domestic unlisted shares of the Company that they held into overseas listed foreign shares.</p>	<p><u>The capital structure of the Company comprises 39,834,408 ordinary shares, including 7,731,890 domestic shares, 536,714 unlisted foreign shares, and 31,565,804 overseas listed foreign shares.</u></p> <p><u>The registered capital of the Company is RMB39,834,408.</u></p>

Article No.	Before amendment	After amendment
	<p>Upon the aforesaid issuance of overseas listed foreign shares (assuming the Over-allotment Option was not exercised) and the conversion of domestic unlisted shares into overseas listed foreign shares, the capital structure of the Company shall comprise of: 38,834,408 ordinary shares, including 6,731,890 domestic shares, 536,714 unlisted foreign shares, and 31,565,804 overseas listed foreign shares (including the 24,963,954 overseas listed foreign shares converted from domestic unlisted shares). Upon the aforesaid issuance of overseas listed foreign shares (assuming the Over-allotment Option was exercised) and the conversion of domestic unlisted shares into overseas listed foreign shares, the capital structure of the Company shall comprise of: 39,824,658 ordinary shares, including 6,731,890 domestic shares, 536,714 unlisted foreign shares, and 32,556,054 overseas listed foreign shares (including the 24,963,954 overseas listed foreign shares converted from domestic unlisted shares):</p> <p>As of the issuance of H shares, the registered share capital of our Company was RMB32,232,558.</p>	

The Company also made other amendments to the Articles of Association as detailed in the announcement of the Company dated April 27, 2026 and the circular of the 2025 annual general meeting of the Company (“AGM”) dated April 27, 2026. A special resolution was duly passed by the Shareholders at the AGM to approve the proposed amendments. The full text of the amended Articles of Association has been published on the HKEXnews website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.heartcare.com.cn).

By order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, June 11, 2026

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.